Alice Y Guh1, Kelly M Hatfield1, Lisa G Winston2, Brittany Martin3, Helen Johnston4, Geoffrey Brousseau4, Monica M Farley5,6, Lucy Wilson7, Rebecca Perlmutter7, Erin C Phipps8,9, Ghinwa K Dumyati10, Deborah Nelson10, Trupti Hatwar10, Marion A Kainer11, Ashley L Paulick1, Maria Karlsson1, Dale N Gerding12,13, L Clifford McDonald1. 1. Centers for Disease Control and Prevention, Atlanta, Georgia. 2. School of Medicine, University of California, San Francisco. 3. California Emerging Infections Program, Oakland. 4. Colorado Department of Public Health and Environment, Denver. 5. Emory University School of Medicine, Atlanta, Georgia. 6. Veterans Affairs Medical Center, Atlanta, Georgia. 7. Maryland Department of Health, Baltimore. 8. University of New Mexico, Albuquerque. 9. New Mexico Emerging Infections Program, Albuquerque. 10. New York Emerging Infections Program and University of Rochester Medical Center, Nashville. 11. Tennessee Department of Health, Nashville. 12. Stritch School of Medicine, Loyola University Chicago, Maywood. 13. Edward Hines Jr Veterans Affairs Hospital, Hines, Illinois.
Abstract
BACKGROUND: Few data suggest that Clostridioides difficile infections (CDIs) detected by toxin enzyme immunoassay (EIA) are more severe and have worse outcomes than those detected by nucleic acid amplification tests (NAATs) only. We compared toxin- positive and NAAT-positive-only CDI across geographically diverse sites. METHODS: A case was defined as a positive C. difficile test in a person ≥1 year old with no positive tests in the prior 8 weeks. Cases were detected during 2014-2015 by a testing algorithm (specimens initially tested by glutamate dehydrogenase and toxin EIA; if discordant results, specimens were reflexed to NAAT) and classified as toxin positive or NAAT positive only. Medical charts were reviewed. Multivariable logistic regression models were used to compare CDI-related complications, recurrence, and 30-day mortality between the 2 groups. RESULTS: Of 4878 cases, 2160 (44.3%) were toxin positive and 2718 (55.7%) were NAAT positive only. More toxin-positive than NAAT-positive-only cases were aged ≥65 years (48.2% vs 38.0%; P < .0001), had ≥3 unformed stools for ≥1 day (43.9% vs 36.6%; P < .0001), and had white blood cell counts ≥15 000 cells/µL (31.4% vs 21.4%; P < .0001). In multivariable analysis, toxin positivity was associated with recurrence (adjusted odds ratio [aOR], 1.89; 95% confidence interval [CI], 1.61-2.23), but not with CDI-related complications (aOR, 0.91; 95% CI, .67-1.23) or 30-day mortality (aOR, 0.95; 95% CI, .73-1.24). CONCLUSIONS: Toxin-positive CDI is more severe, but there were no differences in adjusted CDI-related complication and mortality rates between toxin-positive and NAAT-positive-only CDI that were detected by an algorithm that utilized an initial glutamate dehydrogenase screening test. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND: Few data suggest that Clostridioides difficile infections (CDIs) detected by toxin enzyme immunoassay (EIA) are more severe and have worse outcomes than those detected by nucleic acid amplification tests (NAATs) only. We compared toxin- positive and NAAT-positive-only CDI across geographically diverse sites. METHODS: A case was defined as a positive C. difficile test in a person ≥1 year old with no positive tests in the prior 8 weeks. Cases were detected during 2014-2015 by a testing algorithm (specimens initially tested by glutamate dehydrogenase and toxin EIA; if discordant results, specimens were reflexed to NAAT) and classified as toxin positive or NAAT positive only. Medical charts were reviewed. Multivariable logistic regression models were used to compare CDI-related complications, recurrence, and 30-day mortality between the 2 groups. RESULTS: Of 4878 cases, 2160 (44.3%) were toxin positive and 2718 (55.7%) were NAAT positive only. More toxin-positive than NAAT-positive-only cases were aged ≥65 years (48.2% vs 38.0%; P < .0001), had ≥3 unformed stools for ≥1 day (43.9% vs 36.6%; P < .0001), and had white blood cell counts ≥15 000 cells/µL (31.4% vs 21.4%; P < .0001). In multivariable analysis, toxin positivity was associated with recurrence (adjusted odds ratio [aOR], 1.89; 95% confidence interval [CI], 1.61-2.23), but not with CDI-related complications (aOR, 0.91; 95% CI, .67-1.23) or 30-day mortality (aOR, 0.95; 95% CI, .73-1.24). CONCLUSIONS: Toxin-positive CDI is more severe, but there were no differences in adjusted CDI-related complication and mortality rates between toxin-positive and NAAT-positive-only CDI that were detected by an algorithm that utilized an initial glutamate dehydrogenase screening test. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Authors: Abraham Goorhuis; Dennis Bakker; Jeroen Corver; Sylvia B Debast; Celine Harmanus; Daan W Notermans; Aldert A Bergwerff; Frido W Dekker; Ed J Kuijper Journal: Clin Infect Dis Date: 2008-11-01 Impact factor: 9.079
Authors: Dubert M Guerrero; Christina Chou; Lucy A Jury; Michelle M Nerandzic; Jennifer C Cadnum; Curtis J Donskey Journal: Clin Infect Dis Date: 2011-08-01 Impact factor: 9.079
Authors: Yilen K Ng Wong; Melany Gonzalez-Orta; Carlos Saldana; Jennifer L Cadnum; Annette L Jencson; Curtis J Donskey Journal: Clin Infect Dis Date: 2019-02-01 Impact factor: 9.079
Authors: J Origüen; L Corbella; M Á Orellana; M Fernández-Ruiz; F López-Medrano; R San Juan; M Lizasoain; T Ruiz-Merlo; A Morales-Cartagena; G Maestro; P Parra; J Villa; R Delgado; J M Aguado Journal: Clin Microbiol Infect Date: 2017-08-12 Impact factor: 8.067
Authors: Nira R Pollock; Alice Banz; Xinhua Chen; David Williams; Hua Xu; Christine A Cuddemi; Alice X Cui; Matthew Perrotta; Eaman Alhassan; Brigitte Riou; Aude Lantz; Mark A Miller; Ciaran P Kelly Journal: Clin Infect Dis Date: 2019-01-01 Impact factor: 9.079
Authors: Fred C Tenover; Susan Novak-Weekley; Christopher W Woods; Lance R Peterson; Thomas Davis; Paul Schreckenberger; Ferric C Fang; Andre Dascal; Dale N Gerding; Jim H Nomura; Richard V Goering; Thomas Akerlund; Alice S Weissfeld; Ellen Jo Baron; Edith Wong; Elizabeth M Marlowe; Joseph Whitmore; David H Persing Journal: J Clin Microbiol Date: 2010-08-11 Impact factor: 5.948
Authors: Christopher R Polage; Clare E Gyorke; Michael A Kennedy; Jhansi L Leslie; David L Chin; Susan Wang; Hien H Nguyen; Bin Huang; Yi-Wei Tang; Lenora W Lee; Kyoungmi Kim; Sandra Taylor; Patrick S Romano; Edward A Panacek; Parker B Goodell; Jay V Solnick; Stuart H Cohen Journal: JAMA Intern Med Date: 2015-11 Impact factor: 21.873
Authors: Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245
Authors: Carolyn D Alonso; Ciarán P Kelly; Kevin W Garey; Anne J Gonzales-Luna; David Williams; Kaitlyn Daugherty; Christine Cuddemi; Javier Villafuerte-Gálvez; Nicole C White; Xinhua Chen; Hua Xu; Rebecca Sprague; Caitlin Barrett; Mark Miller; Agnès Foussadier; Aude Lantz; Alice Banz; Nira R Pollock Journal: Clin Infect Dis Date: 2022-07-06 Impact factor: 20.999
Authors: Alice Y Guh; Sarah H Yi; James Baggs; Lisa Winston; Erin Parker; Helen Johnston; Elizabeth Basiliere; Danyel Olson; Scott K Fridkin; Nirja Mehta; Lucy Wilson; Rebecca Perlmutter; Stacy M Holzbauer; Paige D'Heilly; Erin C Phipps; Kristina G Flores; Ghinwa K Dumyati; Trupti Hatwar; Rebecca Pierce; Valerie L S Ocampo; Christopher D Wilson; Jasmine J Watkins; Lauren Korhonen; Ashley Paulick; Michelle Adamczyk; Dale N Gerding; Sujan C Reddy Journal: Open Forum Infect Dis Date: 2022-08-17 Impact factor: 4.423
Authors: Nieves Sopena; Jun Hao Wang-Wang; Irma Casas; Lourdes Mateu; Laia Castellà; María José García-Quesada; Sara Gutierrez; Josep M Llibre; M Luisa Pedro-Botet; Gema Fernandez-Rivas Journal: Microorganisms Date: 2022-05-23
Authors: Anitha Menon; D Alex Perry; Jonathan Motyka; Shayna Weiner; Alexandra Standke; Aline Penkevich; Micah Keidan; Vincent B Young; Krishna Rao Journal: Clin Infect Dis Date: 2021-11-02 Impact factor: 9.079